SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies (ROLR) is currently trending with explosive trading and multiple halts after announcing a binding strategic partnership with Crypto.com/us to exclusively launch event-based prediction markets in the United States. The community is highly engaged, driving a strong short squeeze narrative and anticipating significant growth as ROLR positions itself as a pioneering player in the trillion-dollar prediction market space with a major crypto partner.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is seeing significant market activity and community buzz, fueled by an anticipated presence at the J.P. Morgan Healthcare Conference and a recent positive analyst rating. High short interest remains a key talking point, with many investors speculating about a potential short squeeze and closely watching for strategic updates regarding its Matrix-M platform. While some anticipate a major breakout, others express ongoing skepticism and frustration with management's perceived lack of execution.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid reports of a revised all-cash offer for Warner Bros. Discovery's studio and streaming assets, a move seen by many as a strategic effort to eliminate shareholder dilution and secure the deal against competing bids. The community is sharply divided, with some viewing this as a bullish sign of confidence in upcoming earnings and a path to media empire expansion, while others voice concerns about increased debt and potential overvaluation. This development, coupled with anticipation for the impending earnings report, is driving extensive discussion around the stock's immediate future.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is actively trending following recent analyst downgrades, which many in the community view as an orchestrated move to drive down share price ahead of key future developments. This has sparked a heated debate, with bullish investors aggressively buying the dip, confident in the impending R2 vehicle launch and potential for a significant market rebound.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending following strong preliminary revenue and optimistic guidance for its MS drug Briumvi, which is driving substantial community discussion. Many traders believe the biotech is significantly undervalued and poised for future growth toward blockbuster status, despite ongoing market volatility and active short interest. Enthusiasm is also fueled by expectations for further pipeline developments in the competitive multiple sclerosis treatment landscape.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is buzzing with activity, driven by compelling clinical data for its Alpha DaRT therapy in pancreatic cancer and high anticipation for Japanese market approval. Community discussions are focused on the company's prominent presence at a major healthcare conference and emerging institutional interest, signaling a potential revaluation for its innovative precision oncology approach.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is seeing significant buzz driven by its Gemini-II APU, with recent news of a government-funded proof-of-concept for Edge AI autonomous security systems and upcoming presentations at the Needham Growth Conference. The community is sharply divided; while bulls highlight its low-power, compute-in-memory AI for defense and drone applications and anticipate major contracts, skeptics point to historical losses, dilution, and previous product failures. This heightened interest reflects a broader market focus on efficient AI inference solutions, where GSIT aims to differentiate its technology from power-hungry alternatives.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is currently trending as Bitcoin demonstrates renewed strength and the community anticipates progress on the "Clarity Act" crypto bill in the Senate, which could provide significant regulatory certainty. While bulls anticipate substantial upside driven by recent analyst upgrades and Coinbase's expanding product offerings like tokenization, many express frustration over its perceived underperformance relative to Bitcoin's rallies and ongoing market volatility. The confluence of crypto market momentum and potential regulatory clarity fuels intense debate and investor interest around the stock.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is trending amid multiple analyst upgrades, underscoring its strengthened position in mobile gaming advertising, the promising Vector AI platform, and new payment solutions. The community is actively debating Unity's competitive advantages in its ecosystem against rivals, with many anticipating a significant breakout fueled by these strategic initiatives.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending following its definitive agreement to acquire significant land and transmission facilities in Texas for a large-scale data center, marking a strategic expansion into AI and high-performance computing. Community discussion centers on the immense growth potential this move presents, though some investors remain cautious, awaiting concrete AI customer deals to validate the new infrastructure investments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Veeva Systems (VEEV) Surpasses Q2 Earnings and Revenue Estimates

Veeva (VEEV) delivered earnings and revenue surprises of +4.74% and +2.80%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +43.48% and -31.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

VAXART (VXRT) delivered earnings and revenue surprises of +22.22% and +1,206.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of +29.69% and -7.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.85% and -79.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates

Bioventus (BVS) delivered earnings and revenue surprises of -4.55% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates

Indivior (INDV) delivered earnings and revenue surprises of +96.15% and +22.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates

Shares of CASI Pharmaceuticals, Inc. (CASI) traded 5% higher on Thursday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=6899273834937655">announced</a> that it has received a buyout proposal valuing the company’s operations in China at $20 million.The proposal, dated April 2, was put forth by company CEO Wei-Wu He and covers the company’s entire business operations in China and all license-in, distribution, and related rights in Asia, excluding Japan, related to certain pipeline products.CASI said the proposal updates the preliminary non-binding proposal letter submitted by He to the company on June 21, 2024.The company said that its special committee of the board of directors will evaluate the proposed transaction. However, no decisions have been made regarding the proposal letter or any alternative strategic option the company may pursue. &nbsp;The company added that there is no assurance that any definitive agreement relating to the proposal letter will be entered between the company and its CEO.On Stocktwits, retail sentiment about CASI Pharmaceuticals dipped slightly within the ‘extremely bullish’ territory (94/100), accompanied by a slight drop in message volume over the past 24 hours.<figure class="image"><img style="aspect-ratio:654/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_03_at_1_58_58_PM_png_20cfaa728f.webp" alt="CASI's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 3, 2025 | Source: Stocktwits" width="654" height="149"><figcaption>CASI's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 3, 2025 | Source: Stocktwits</figcaption></figure> Late last month, CASI Pharma reported full-year 2024 revenue of $28.5 million, a decrease of 16% compared to 2023. The company noted that it was impacted by intensified competition and increased pricing pressure during the year.Net loss for the year came in at $39.3 million, higher than the $26.3 million reported in 2023.The company added that it had cash and cash equivalents of $13.5 million as of the end of 2024, less than the $29.1 million as of 2023-end.<a href="https://stocktwits.com/symbol/CASI">CASI shares</a> are down by over 25% this year and over 30% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/gm-marks-marginal-sales-growth-in-china-in-q1/chf7IpJRbeZ">GM Marks Marginal Sales Growth In China In Q1: But Retail Continues To Stay Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish

The company said that its special committee of the board of directors will evaluate the proposed transaction.

Equity

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The firm is also involved in developing innovative therapeutics addressing cancer and other unmet medical needs for the global market. The company was founded in 1991 and is headquartered in Beijing, China.

CASI Pharmaceuticals Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$1.04
Prev Close	$1.08
Open	$1.08
Dividend Yield	0.00%
50-Day Moving Average	$1.04
Beta	0.46
Avg. Volume	36,242.95
PE Ratio	-0.33

52-Week High	$3.09
52-Week Low	$0.75
Market Capitalization	$16.54M
EPS (Annual)	-$2.56
Price to Book	-0.63
Revenue Per Employee	$122,476.40
Enterprise Value/EBITDA	N/A

CASI
CASI Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CASI News

CASICASI Pharmaceuticals Inc